Dataset from An Open-label, Randomized, Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects With Metastatic Colorectal Cancer

The purpose of this study is to determine that panitumumab, using the proposed regimen, will safely increase progression free survival in patients with metastatic colorectal cancer who have failed available treatment options (i.e., patients who developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy).

本研究旨在验证采用本次拟定治疗方案的帕尼单抗（panitumumab），能否安全延长经现有治疗失败的转移性结直肠癌（metastatic colorectal cancer）患者的无进展生存期（progression free survival）。此类患者具体指在既往接受氟嘧啶类（fluoropyrimidine）、伊立替康（irinotecan）及奥沙利铂（oxaliplatin）化疗期间或之后出现疾病进展或复发的人群。